(Press-News.org) Baltimore, Md. (embargoed until 12:30 p.m. EDT, June 8, 2015) - Research presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a new molecular imaging agent finds prostate cancer that has spread to other tissues by locking in on an enzyme called prostate specific membrane antigen (PSMA), associated with prostate cancer.
"To date, conventional imaging is limited in detecting prostate cancer metastasis accurately and measurably," said Neeta Pandit-Taskar, MD, co-author of the study and a researcher at Memorial Sloan Kettering Cancer Center in New York City. "Using this agent, we can detect the prostate cancer cells that have metastasized to bone--one of the most difficult areas to evaluate using standard methods. We hope that this research will help us develop earlier and more effective detection of disease and assist in clinical decision-making."
The radiotracer combines a small amount of the radioactive material zirconium-89 with a fragment of an antibody called a minibody. This minibody has anti-PSMA qualities and attaches to overexpression of the enzyme (more technically known as glutamate carboxypeptidase II or GCPII) on the exterior of prostate cancer cells wherever they may have traveled in the body. The novel radiotracer, called Zr-89 Df-IAB2M (IAB2M), is imaged faster than the full antibody (J591) that targets PSMA and has been shown to be safe for patients. Particles emitted from the site are then detected by positron emission tomography (PET), which creates a computerized image of the activity of the agent within the body. The resulting scan highlights "hot spots" of PSMA overexpression.
"Initial results of full-body imaging with this Zr-89 radiolabeled minibody have shown that we are able to detect more disease sites in patients than with conventional imaging," said Pandit-Taskar. "With further validation, this radiotracer could also potentially be used to perform targeted biopsies for precise tissue analysis, which could lead to earlier, more appropriate treatment for prostate cancer patients."
For this research, a total of 28 subjects were imaged with a variety of imaging modalities, including standard imaging with computed tomography, magnetic resonance imaging and molecular bone scan (SI); PET with a common radiotracer called fluorodeoxyglucose (FDG-PET); and PET with computed tomography and the agent Zr-89 IAB2M (IAB2M PET/CT) assessed in escalated doses. A selection of suspected disease sites were then biopsied.
Results of the study showed that there were a total of 393 suspected lesions found in soft tissue and bone using all imaging modalities, collectively. IAB2M PET/CT identified 81.7 percent of all suspected bone lesions, and 65 of these growths that were not identified with any other modalities. Additionally, IAB2M found 32 soft tissue lesions not found by other methods.
Of the total 19 biopsies and histological analyses performed, FDG-PET identified 14 growths, IAB2M PET/CT-identified 17 growths, and SI found 18. However, overall accuracy of positive/negative reading was found to be 89.5 percent for IAB2M PET/CT versus 84 percent for SI and 84 percent for FDG-PET.
"This is an early phase trial," said Pandit-Taskar. "For the next few years, we will be exploring IAB2M in additional clinical trials. More data are needed to understand its clinical value but, if results are favorable, this imaging agent could play a critical role in the standard of care for prostate cancer."
An estimated 220,800 new cases of prostate cancer and 27,540 prostate-cancer related deaths occur annually in the U.S. alone. As many as one out of every seven American men are expected to be diagnosed with prostate cancer at some point in their lifetime, according to 2015 statistics from the American Cancer Society.
INFORMATION:
Scientific Paper 400: "First in Human 89Zr-Df-IAB2M anti-prostate specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer," N.D. Pandit-Taskar, J.A. O'Donoghue, D.F. Martinez, S.K. Lyashchenko, J.A. Carrasquillo, J. Durack, H. Scher, S.M. Larson, M.J. Morris, Memorial Sloan-Kettering Cancer Center, New York, N.Y.; J.S. Keppler, ImaginAb Inc., Inglewood, Calif.; SNMMI's 62nd Annual Meeting, June 6-10, 2015, Baltimore, Md.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI's 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.
A recently developed tool can accurately predict the risk of death for patients within 1 year after admission to hospital using routinely collected data, reports a study in CMAJ (Canadian Medical Association Journal).
"An accurate assessment of risk of death, particularly if that risk is high, could motivate and inform discussions between patients and physicians regarding goals of care," states Dr. Carl van Walraven, a researcher at the Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, who developed the tool.
Researchers in Canada and the United States ...
Baltimore, Md. -- Scientists are taking medical imaging research and drug discovery to a new level by developing a molecular imaging system that combines several advanced technologies for all-in-one imaging of both tissue models and live subjects, say presenters at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The preclinical and intra-vital molecular imaging system houses a window for tissue observation in addition to a larger imaging chamber. Together they are being used to peer into the microenvironment of tumors and other ...
Baltimore, Md. (Embargoed until 12:30 p.m., June 8, 2015) - The origin of cancer is often obscured by metastases--tumors that have already spread to other tissues. This is especially the case for neuroendocrine tumors (NETs), a malignancy of nerve cells scattered throughout various organ systems that are sensitive to the signaling of neurotransmitters and hormones. An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). ...
Baltimore, Md. -- A relatively new biomarker called prostate-specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
'We have shown in this proof-of-concept study that PSMA could serve as a biomarker for MR-based molecular imaging due to its high concentration within target cells, limited expression within non-targeted ...
Baltimore, Md. -- Amyloid build-up is commonly talked about in relation to Alzheimer's disease, but amyloidosis can be found throughout the body. An excessive accumulation of these insoluble proteins could cause a heart attack or even death. A new molecular imaging scan of amyloid in the heart could help diagnose the problem, say researchers at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
The condition is called transthyretin-type (TTR) amyloidosis after the TTR gene thought to cause the over-abundance of plaque build-up. ...
Baltimore, Md. -- New research presented during the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that amyloid positron emission tomography (amyloid PET) scans of the brain provide clearer diagnosis and earlier, more effective treatment for Alzheimer's patients, when results of a more conventional PET scan remain ambiguous.
Researchers reviewed the clinical outcomes of two kinds of PET scans: a preliminary scan with a common radiotracer called fluorodeoxyglucose (FDG), which acts like glucose in the brain to capture ...
Baltimore, Md. -- Fatal cardiac events are often preceded by abnormal blood clots, also called thrombosis. Scientists have now developed a molecular imaging technique that could save lives by revealing troublesome thrombi, according to a study presented at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
'Thrombosis is the underlying cause of deadly diseases such as stroke, pulmonary embolism, deep vein thrombosis and heart attack, which affect millions of people worldwide,' said Francesco Blasi, Ph.D., lead author of the study ...
Baltimore, Md. (Embargoed until 12:30 p.m., June 8, 2015) - Neuroinflammation caused by a reactive immune system could be tripping off the neurodegeneration seen in certain dementias, multiple sclerosis, and other deadly diseases of the nervous system. A novel molecular imaging technique could be the key to understanding how best to treat these and other devastating diseases, according to a recent study presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
At the heart of this maladaptive immune response are microglia, ...
Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade.
In a cover story set to appear in the journal Cancer Cell online June 8, researchers at NYU Langone and elsewhere report that they have successfully halted and reversed the growth of certain cancerous white blood cells at the center of T-cell ...
A research group at Disney Research Pittsburgh has developed a computer vision system that, much like humans, can continuously improve its ability to recognize objects by picking up hints while watching videos.
Like most other object recognition systems, the Disney system builds a conceptual model of an object, be it an airplane or a soap dispenser, by using a learning algorithm to analyze a number of example images of the object.
What's different about the Disney system is that it then uses that model to identify objects, when it can, in videos. As it does, it sometimes ...
